Tools of the Trade: How McKesson’s Intrafusion Improves Infusion Center Efficiency, Biosimilar Utilization

On this week’s episode, we’re taking a look at a new health technology tool that could help improve biosimilar utilization and patient care within infusion centers. Many infusion medications are biologic drugs and juggling multiple biosimilars for the same reference product can place undue burden on infusion centers and result in medication errors, such as accidentally administering a product not covered by a patient’s insurance. McKesson’s Intrafusion service enables better efficiency within infusion centers and relieves some of the pressure providers and administrators face when trying to manage infusion facilities, including managing biosimilar administration.

Today, I’m joined by Cheryl Vaughn, vice president of clinical services at McKesson. She has worked closely with McKesson’s Intrafusion team to help develop the tool and has been with the company for over 5 years. She also has over 8 years of experience working as a registered nurse prior to her time at McKesson.